Likewise, VEGF-C treatment prevented the impairment in the latency to move test (LTM) of stroke mice, implying that the VEGF-C treatment also improved alertness and spontaneous activity of stroke mice although it did not decrease lesion size or brain edema. This evidence concerns the gene VEGFC and stroke disorder.